Merck Expands Manufacturing Site In China As Part Of Its Global Restructuring Program
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Merck announced it would invest $162 million to expand its capacity in China by building a new manufacturing facility, shortly after the company detailed its plans to integrate its R&D, manufacturing and business operations worldwide
You may also be interested in...
Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.
Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.
A Closer Look At China’s 2012 Essential Drug Expansion
China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.